

Key Updates for Week 44, ending October 31, 2020

Seasonal influenza activity in the United States remains low.

Viruses

Clinical Lab

The percentage of respiratory specimens testing positive for influenza at clinical laboratories is 0.1% this week.

Public Health Lab

Influenza activity was low during the summer months and few specimens have tested positive in public health labs during recent weeks.

Virus Characterization

Influenza virus characterization information will be updated weekly starting later this season.

Illness

Outpatient Illness: ILINet

1.3% of visits to a health care provider were for ILI, which was a slight increase from the previous week (1.2%). ILI activity remains **below** the national baseline of 2.6%.

Outpatient Illness: ILINet Activity Map

This week, one jurisdiction experienced moderate ILI activity, one experienced low activity, and the remaining jurisdictions experienced minimal activity.

Severe Disease

Hospitalizations

Hospitalization rates will be updated weekly starting later this season.

NCHS Mortality

8.1% of deaths were attributed to pneumonia, influenza, or COVID-19 (PIC). This is **above** the epidemic threshold of 6.0%.

Pediatric Deaths

One influenza-associated pediatric death occurring during the 2019-20 season was reported to CDC, bringing the total for that season to 195. No deaths occurring during the 2020-21 season were reported.

All data are preliminary and may change as more reports are received.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the [surveillance methods](#) page.

Additional information on the current and previous influenza seasons for each surveillance component are available on [FluView Interactive](#).

Key Points

- An annual flu vaccine is the best way to protect against flu and its potentially serious complications.
- CDC recommends everyone 6 months and older get a flu vaccine by the end of October.
- There are also flu antiviral drugs that can be used to treat flu illness.


U.S. Virologic Surveillance

Clinical Laboratories

The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

	Week 44	Data Cumulative since September 27, 2020 (Week 40)
No. of specimens tested	16,456	71,814
No. of positive specimens (%)	21 (0.1%)	191 (0.3%)
Positive specimens by type		
Influenza A	13 (61.9%)	102 (53.4%)
Influenza B	8 (38.1%)	89 (46.6%)

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, September 29, 2019 – October 31, 2020




Public Health Laboratories

The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage.

	Week 44	Data Cumulative since September 27, 2020 (Week 40)
No. of specimens tested	16,139	57,877
No. of positive specimens	17	35
Positive specimens by type/subtype		
Influenza A	5 (29.4%)	20 (57.1%)
(H1N1)pdm09	0 (0%)	1 (50.0%)
H3N2	0 (0%)	1 (50.0%)
Subtyping not performed	5	18
Influenza B	12 (70.6%)	15 (42.9%)
Yamagata lineage	0 (0.0%)	0 (0%)
Victoria lineage	1(100%)	2 (100%)
Lineage not performed	11	13

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, September 29, 2019 – October 31, 2020



Additional virologic surveillance information for current and past seasons:
[Surveillance Methods](#) | FluView Interactive: [National, Regional, and State Data](#) or [Age Data](#)
Influenza Virus Characterization

CDC performs [genetic](#) and [antigenic](#) characterization of U.S. viruses submitted from state and local health laboratories using Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses representing viruses contained in the current influenza vaccines and to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of influenza viruses to antiviral medications, including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.

Virus characterization data will be updated weekly starting later this season when a sufficient number of specimens have been tested.


Outpatient Illness Surveillance

ILINet

Nationwide during week 44, 1.3% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is below the national baseline of 2.6%.

Healthcare seeking behaviors have changed dramatically during the COVID-19 pandemic. While outpatient ILI activity remains low, many people are accessing the healthcare system in alternative settings. Therefore, while traditional healthcare providers are not seeing increased numbers of cases of ILI, it is important to evaluate other sources of surveillance data to obtain a complete and accurate picture of both COVID-19 and influenza activity. CDC is tracking the COVID-19 pandemic in a weekly publication called [COVIDView](#).

Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2020-2021 and Selected Previous Seasons




All regions reported a percentage of outpatient visits for ILI below their region-specific baselines.


ILI Activity Map

Data collected in ILINet are used to produce a measure of [ILI activity*](#) by state/jurisdiction and Core Based Statistical Areas (CBSA).


Activity Level	Number of Jurisdictions		Number of CBSAs	
	Week 44 (Week ending Oct. 31, 2020)	Week 43 (Week ending Oct. 24, 2020)	Week 44 (Week ending Oct. 31, 2020)	Week 43 (Week ending Oct. 24, 2020)
Very High	0	0	0	0
High	0	0	2	1
Moderate	1	0	4	1
Low	1	1	38	27
Minimal	52	53	544	567
Insufficient Data	0	0	341	333



ILI Activity Level Map by Jurisdiction
Week 44, ending October 31, 2020



ILI Activity Level Map by CBSA
Week 44, ending October 31, 2020



*Data collected in ILINet may disproportionately represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

Additional information about medically attended visits for ILI for current and past seasons:
[Surveillance Methods](#) | FluView Interactive: [National, Regional, and State Data](#) or [ILI Activity Map](#)

[Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists](#)

The geographic spread of influenza as reported by state and territorial epidemiologists indicates geographic spread of influenza viruses but does not measure the severity of influenza activity. Due to the impact of COVID-19 on ILI surveillance, and the fact that the state and territorial epidemiologists report relies heavily on ILI activity, reporting for this system will be suspended for the 2020-21 influenza season. Data from previous seasons is available on FluView Interactive

Additional geographic spread surveillance information for current and past seasons:
[Surveillance Methods](#) | [FluView Interactive](#)

[Influenza-Associated Hospitalizations](#)

The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in the Emerging Infections Program (EIP) states and Influenza Hospitalization Surveillance Project (IHSP) states. FluSurv-NET estimated hospitalization rates will be updated weekly starting later this season.


Additional hospitalization surveillance information for current and past seasons and additional age groups:
[Surveillance Methods](#) | [FluView Interactive](#)

National Center for Health Statistics (NCHS) Mortality Surveillance

Based on NCHS mortality surveillance data available on November 5, 2020, 8.1% of the deaths occurring during the week ending October 31, 2020 (week 44), were due to pneumonia, influenza, and COVID-19 (PIC). This percentage is above the epidemic threshold of 6.0% for week 44.

Weekly mortality surveillance data include a combination of machine coded and manually coded causes of death collected from death certificates. Percentages of deaths due to pneumonia, influenza, or COVID-19 (PIC) are higher among manually coded records than more rapidly available machine coded records. Due to the additional time needed for manual coding, the initially reported PIC percentages are likely to increase as more data are received and processed.

Pneumonia, Influenza, and COVID-19 Mortality from the National Center for Health Statistics Mortality Surveillance System Data through the week ending October 31, 2020, as of November 5, 2020



Additional pneumonia and influenza mortality surveillance information for current and past seasons:


[Surveillance Methods](#) | [FluView Interactive](#)

Influenza-Associated Pediatric Mortality

No influenza-associated pediatric deaths occurring during the 2020-21 season have been reported to CDC.

One influenza-associated pediatric death was reported to CDC during week 44. This death occurred during the 2019-2020 influenza season bringing the total number of deaths occurring during that season to 195. It was associated with an influenza B virus with no lineage determined and occurred during week 2 (the week ending January 11, 2020).

Number of Influenza-Associated Pediatric Deaths by Week of Death, 2017-2018 season to 2020-2021 season



Additional pediatric mortality surveillance information for current and past seasons:
[Surveillance Methods](#) | [FluView Interactive](#)

Additional national and international influenza surveillance information is available at:
<https://www.cdc.gov/flu/weekly/#AddInfo>

Report prepared: November 7, 2020

**WHO Collaborating Laboratory Reports
2020-2021 Influenza Season**

National

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202040	60	11228	2	0	0	0	0	0	0	271	11815	39	0.33	19	20
202041	64	11723	3	1	0	0	2	1	0	264	14447	57	0.39	30	27
202042	62	9263	2	0	0	0	0	0	0	250	14094	42	0.30	23	19
202043	65	9524	6	0	1	0	0	0	0	229	15002	32	0.21	17	15
202044	49	16139	5	0	0	0	11	1	0	182	16456	21	0.13	13	8
Total	0	57877	18	1	1	0	13	2	0	.	71814	191	0.27	102	89

Region 1 (CT, ME, MA, NH, RI, VT)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202040	3	22	0	0	0	0	0	0	0	15	653	0	0.00	0	0
202041	3	43	0	0	0	0	0	0	0	15	788	1	0.13	0	1
202042	2	36	0	0	0	0	0	0	0	15	733	2	0.27	0	2
202043	6	23	0	0	0	0	0	0	0	14	728	0	0.00	0	0
202044	5	30	0	0	0	0	0	0	0	12	880	0	0.00	0	0
Total	0	154	0	0	0	0	0	0	0	.	3782	3	0.08	0	3

Region 2 (NJ, NY, PR)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202040	3	14	0	0	0	0	0	0	0	12	1064	0	0.00	0	0
202041	5	8	0	0	0	0	0	0	0	12	1441	0	0.00	0	0
202042	6	7	0	0	0	0	0	0	0	11	1656	5	0.30	2	3
202043	6	7	0	0	0	0	0	0	0	11	1701	6	0.35	4	2
202044	6	18	0	0	0	0	0	0	0	11	3772	0	0.00	0	0
Total	0	54	0	0	0	0	0	0	0	.	9634	11	0.11	6	5

Region 3 (DE, DC, MD, PA, VA, WV)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202040	6	43	0	0	0	0	0	0	0	15	1239	7	0.56	4	3
202041	6	68	0	0	0	0	0	0	0	15	1371	0	0.00	0	0
202042	6	61	0	0	0	0	0	0	0	14	1435	0	0.00	0	0
202043	4	37	0	0	0	0	0	0	0	14	1558	0	0.00	0	0
202044	7	48	0	0	0	0	0	0	0	12	1474	0	0.00	0	0



CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
Total	0	257	0	0	0	0	0	0	0	.	7077	7	0.10	4	3

Region 4 (AL, FL, GA, KY, MS, NC, SC, TN)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202040	8	43	0	0	0	0	0	0	0	25	1451	11	0.76	5	6
202041	8	54	0	0	0	0	0	0	0	24	1686	16	0.95	8	8
202042	7	45	0	0	0	0	0	0	0	25	1657	15	0.91	9	6
202043	5	908	0	0	0	0	0	0	0	25	1796	7	0.39	2	5
202044	5	3779	2	0	0	0	2	1	0	21	1628	9	0.55	7	2
Total	0	4829	2	0	0	0	2	1	0	.	8218	58	0.71	31	27

Region 5 (IL, IN, MI, MN, OH, WI)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202040	4	39	0	0	0	0	0	0	0	115	2038	4	0.20	2	2
202041	5	43	0	0	0	0	0	0	0	111	2715	12	0.44	9	3
202042	6	53	0	0	0	0	0	0	0	102	2689	9	0.33	5	4
202043	7	44	0	0	0	0	0	0	0	86	2640	10	0.38	5	5
202044	3	20	0	0	0	0	0	0	0	63	2003	4	0.20	4	0
Total	0	199	0	0	0	0	0	0	0	.	12085	39	0.32	25	14

Region 6 (AR, LA, NM, OK, TX)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202040	5	51	0	0	0	0	0	0	0	28	1526	16	1.05	7	9
202041	6	73	0	1	0	0	0	1	0	29	1836	21	1.14	11	10
202042	6	114	0	0	0	0	0	0	0	26	1291	3	0.23	1	2
202043	7	90	0	0	0	0	0	0	0	24	1216	2	0.16	0	2
202044	5	31	0	0	0	0	0	0	0	19	1257	2	0.16	1	1
Total	0	359	0	1	0	0	0	1	0	.	7126	44	0.62	20	24

Region 7 (IA, KS, MO, NE)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202040	5	15	1	0	0	0	0	0	0	14	859	0	0.00	0	0
202041	5	19	0	0	0	0	0	0	0	12	953	1	0.10	0	1



CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202042	3	10	0	0	0	0	0	0	0	11	599	1	0.17	1	0
202043	3	8	0	0	0	0	0	0	0	11	1061	0	0.00	0	0
202044	4	25	0	0	0	0	0	0	0	10	1126	0	0.00	0	0
Total	0	77	1	0	0	0	0	0	0	.	4598	2	0.04	1	1

Region 8 (CO, MT, ND, SD, UT, WY)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202040	3	4181	1	0	0	0	0	0	0	12	1595	0	0.00	0	0
202041	4	4579	3	0	0	0	0	0	0	11	1788	0	0.00	0	0
202042	7	3615	1	0	0	0	0	0	0	11	1819	3	0.16	2	1
202043	4	28	0	0	0	0	0	0	0	11	2023	2	0.10	2	0
202044	4	6694	3	0	0	0	0	0	0	10	2762	2	0.07	0	2
Total	0	19097	8	0	0	0	0	0	0	.	9987	7	0.07	4	3

Region 9 (AZ, CA, GU, HI, NV)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202040	28	6797	0	0	0	0	0	0	0	14	805	1	0.12	1	0
202041	28	6770	0	0	0	0	2	0	0	15	1051	3	0.29	1	2
202042	29	5291	1	0	0	0	0	0	0	14	1348	1	0.07	1	0
202043	29	8366	6	0	1	0	0	0	0	14	1340	2	0.15	2	0
202044	28	5473	0	0	0	0	9	0	0	5	528	1	0.19	0	1
Total	0	32697	7	0	1	0	11	0	0	.	5072	8	0.16	5	3

Region 10 (AK, ID, OR, WA)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
202040	3	23	0	0	0	0	0	0	0	22	585	0	0.00	0	0
202041	4	66	0	0	0	0	0	0	0	23	818	3	0.37	1	2
202042	3	31	0	0	0	0	0	0	0	21	867	3	0.35	2	1
202043	3	13	0	0	0	0	0	0	0	19	939	3	0.32	2	1
202044	2	21	0	0	0	0	0	0	0	19	1026	3	0.29	1	2
Total	0	154	0	0	0	0	0	0	0	.	4235	12	0.28	6	6

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2020-2021 Influenza Season
National (Baseline: 2.6%)
Data as of Friday, October 31, 2020**

CDC Week	# Sites Reporting	ILI 0-4 years	ILI 5-24 years	ILI 25-49 years	ILI 50-64 years	ILI 65 years and older	Total ILI	Total Patient Visits	% Unweighted ILI	% Weighted ILI
202040	3124	2399	4550	4920	2300	1783	15952	1453172	1.1	1.1
202041	3140	2435	5028	5810	2904	2235	18412	1524010	1.2	1.2
202042	3122	2235	4446	5486	2460	2022	16649	1491371	1.1	1.1
202043	3068	2377	4751	5622	2788	2068	17606	1474489	1.2	1.2
202044	2918	2193	4519	5522	2600	2040	16874	1340812	1.3	1.3

HHS Region 1 (CT, ME, MA, NH, RI, and VT) (Baseline: 2.0%)

CDC Week	# Sites Reporting	ILI 0-4 years	ILI 5-24 years	ILI 25-49 years	ILI 50-64 years	ILI 65 years and older	Total ILI	Total Patient Visits	% Unweighted ILI	% Weighted ILI
202040	256	109	293	324	180	131	1037	135827	0.8	0.8
202041	260	95	322	379	230	177	1203	138649	0.9	0.8
202042	259	92	354	373	180	145	1144	132850	0.9	0.8
202043	258	123	460	407	309	171	1470	134687	1.1	1.1
202044	258	103	499	468	293	179	1542	121115	1.3	1.2

HHS Region 2 (NJ, NY, PR, and USVI) (Baseline: 3.3%)

CDC Week	# Sites Reporting	ILI 0-4 years	ILI 5-24 years	ILI 25-49 years	ILI 50-64 years	ILI 65 years and older	Total ILI	Total Patient Visits	% Unweighted ILI	% Weighted ILI
202040	236	304	419	429	232	202	1586	148028	1.1	1.5
202041	237	306	438	446	287	228	1705	149461	1.1	1.7
202042	237	259	335	453	221	204	1472	147123	1.0	1.4
202043	232	254	375	501	262	214	1606	143305	1.1	1.7
202044	164	133	213	271	145	144	906	69553	1.3	1.4

HHS Region 3 (DE, DC, MD, PA, VA, and WV) (Baseline: 1.9%)

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
202040	414	259	548	611	278	219	1915	211068	0.9	0.9
202041	392	259	686	815	397	285	2442	209813	1.2	1.1
202042	392	229	475	696	307	253	1960	206826	0.9	0.9
202043	386	224	518	757	308	238	2045	208834	1.0	1.0
202044	379	221	463	737	382	324	2127	200845	1.1	1.1

HHS Region 4 (AL, FL, GA, KY, MS, NC, SC, and TN) (Baseline: 3.1%)

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
202040	883	865	1597	1866	844	668	5840	448151	1.3	1.3
202041	883	988	1800	2263	1101	812	6964	482523	1.4	1.4
202042	888	899	1739	2212	1009	771	6630	481291	1.4	1.4
202043	879	1016	1840	2150	1088	769	6863	480278	1.4	1.5
202044	859	946	1706	2098	904	714	6368	466477	1.4	1.4

HHS Region 5 (IL, IN, MI, MN, OH, and WI) (Baseline: 1.9%)

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
202040	359	178	347	329	148	94	1096	134660	0.8	0.9
202041	361	194	380	378	190	137	1279	137549	0.9	0.9
202042	343	154	340	357	159	133	1143	131599	0.9	0.9
202043	318	152	356	362	180	129	1179	122065	1.0	0.9
202044	309	186	370	414	213	184	1367	120201	1.1	1.2

HHS Region 6 (AR, LA, NM, OK, and TX) (Baseline: 3.9%)

CDC Week	# Sites Reporting	ILI 0-4 years	ILI 5-24 years	ILI 25-49 years	ILI 50-64 years	ILI 65 years and older	Total ILI	Total Patient Visits	% Unweighted ILI	% Weighted ILI
202040	262	339	561	538	231	166	1835	114018	1.6	1.4
202041	288	235	470	471	223	162	1561	128012	1.2	1.4
202042	278	254	435	492	210	150	1541	124417	1.2	1.4
202043	279	264	405	486	200	161	1516	120933	1.3	1.4
202044	262	250	394	459	220	129	1452	110311	1.3	1.5

HHS Region 7 (IA, KS, MO, and NE) (Baseline: 1.7%)

CDC Week	# Sites Reporting	ILI 0-4 years	ILI 5-24 years	ILI 25-49 years	ILI 50-64 years	ILI 65 years and older	Total ILI	Total Patient Visits	% Unweighted ILI	% Weighted ILI
202040	159	75	225	175	83	63	621	50507	1.2	1.3
202041	157	71	248	220	100	92	731	53980	1.4	1.5
202042	159	79	186	170	76	63	574	49429	1.2	1.3
202043	160	78	192	191	95	59	615	50130	1.2	1.3
202044	154	68	234	201	70	81	654	48070	1.4	1.5

HHS Region 8 (CO, MT, ND, SD, UT, and WY) (Baseline: 2.8%)

CDC Week	# Sites Reporting	ILI 0-4 years	ILI 5-24 years	ILI 25-49 years	ILI 50-64 years	ILI 65 years and older	Total ILI	Total Patient Visits	% Unweighted ILI	% Weighted ILI
202040	200	117	187	190	67	53	614	74695	0.8	0.9
202041	198	130	246	226	111	93	806	77305	1.0	1.1
202042	198	115	178	226	83	77	679	73216	0.9	1.0
202043	197	113	216	231	97	87	744	71803	1.0	1.1
202044	196	137	249	269	110	96	861	69564	1.2	1.3

HHS Region 9 (AZ, CA, HI, and NV) (Baseline: 2.4%)

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
202040	178	72	165	185	125	114	661	71644	0.9	1.0
202041	185	75	229	272	150	136	862	78847	1.1	1.1
202042	191	92	226	228	125	145	816	80437	1.0	1.0
202043	186	92	205	272	138	147	854	80158	1.1	1.1
202044	159	89	205	315	137	113	859	71972	1.2	1.2

HHS Region 10 (AK, ID, OR, and WA) (Baseline: 1.6%)

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
202040	174	81	208	272	112	73	746	63793	1.2	1.0
202041	176	82	209	334	109	110	844	67133	1.3	1.1
202042	175	62	177	278	90	81	688	63867	1.1	0.9
202043	171	61	184	265	111	93	714	61970	1.2	1.0
202044	176	60	186	290	126	76	738	62396	1.2	1.0

NCHS Mortality Surveillance Data
Data as of November 5, 2020
For the Week Ending October 31, 2020 (Week 44)

Year	Week	Percent of Deaths Due to Pneumonia and Influenza (P&I)	Percent of Deaths Due to Pneumonia, Influenza or COVID-19 (PIC)	Expected	Threshold	All Deaths	Pneumonia Deaths	Influenza Deaths	COVID-19 Deaths	Pneumonia, Influenza or COVID-19 Deaths (PIC)
2020	40	7.82	11.32	5.32	5.62	54450	4249	7	3641	6166
2020	41	8.12	11.84	5.39	5.70	54365	4405	10	3981	6435
2020	42	8.26	12.24	5.48	5.78	49591	4084	12	3821	6072
2020	43	7.78	11.79	5.57	5.87	42028	3261	7	3039	4954
2020	44	6.12	8.14	5.67	5.97	20683	1261	4	795	1684